Rezolute, Inc.
  • About Us
    • Mission
    • Leadership
    • Contact
  • Our Focus
    • Hyperinsulinism Therapeutics
    • Publications & Presentations
  • Our Pipeline
    • Development Pipeline
    • Ersodetug
    • Clinical Trials
  • Join Us
    • Our Culture
    • Job Openings
  • Investors & Media
    • Investors Overview
    • Corporate Presentation
    • Press Releases
    • Events
    • Stock Quote & Chart
    • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Investor Contacts
  • for patients
    • Understanding Hyperinsulinism
    • Join the Rezolution
Skip to main content Skip to section navigation Skip to footer
Rezolute, Inc. IR Overview
  • chevron_leftBack to rezolutebio.com
  • Investors Overview
  • Corporate Presentation
  • Press Releases
  • Events
  • Stock Quote & Chart
  • Historical Data
  • Analyst Coverage
  • SEC Filings
  • Governance
    • Governance Documents
  • Investor Contacts

Press Releases

Investors

Investors

  • Investors Overview
  • Corporate Presentation
  • Press Releases
  • Events
  • Stock Quote & Chart
  • Historical Data
  • Analyst Coverage
  • SEC Filings
  • Governance
    • Governance Documents
  • Investor Contacts
Jun 5, 2017 8:00 am EDT
AntriaBio Files Investigational New Drug Application for Once-Weekly Basal Insulin AB101
May 1, 2017 8:00 am EDT
AntriaBio Formally Engages CRO for the Conduct of its Phase I First-in-Human Clinical Trial of AB101
Mar 22, 2017 8:00 am EDT
AntriaBio Appoints Two Pharmaceutical Executives to its Board of Directors
Dec 15, 2016 5:15 pm EST
AntriaBio Announces Offer to Amend Warrants to Purchase Shares of Common Stock
Sep 22, 2016 8:00 am EDT
AntriaBio Announces Formation of Subsidiary and Plan to Raise Capital in South Korea
Jun 29, 2016 8:00 am EDT
AntriaBio Announces $12 Million Private Placement
Jun 22, 2016 8:00 am EDT
AntriaBio Announces Preclinical Proof of Concept for Once-Weekly Basal Insulin AB101 in Diabetic Miniature Swine
Jan 6, 2016 8:30 am EST
AntriaBio Announces Appointment of Michael Deperro as Vice President of Operations
Dec 10, 2015 12:50 pm EST
AntriaBio Announces First Close of Private Placement Transaction
Nov 17, 2015 8:30 am EST
AntriaBio Receives Notice of Allowance on Patent Covering Microsphere Drug Delivery Platform
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Next Pagearrow_forward
rss_feed News RSS

Stay Connected

  • emailEmail Alerts
  • contact_pageContacts
  • rss_feedRSS News Feed
Visit us on LinkedIn Visit us on X Visit us on Facebook
Footer logo

Join our passionate and dedicated team to make a difference for patients.

SEE OPEN JOBS
  • About Us
    • Mission
    • Leadership
    • Contact
  • Our Focus
    • Hyperinsulinism Therapeutics
    • Publications & Presentations
  • Our Pipeline
    • Development Pipeline
    • Ersodetug
    • Clinical Trials
  • Join Us
    • Our Culture
    • Job Openings
  • Investors & Media
    • Investors Overview
    • Corporate Presentation
    • Press Releases
    • Events
    • Stock Quote & Chart
    • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Investor Contacts
  • for patients
    • Understanding Hyperinsulinism
    • Rezolution Community
©2025 Rezolute, Inc. All rights reserved. Privacy Policy Terms of Use
Made by 22 Fillmore